Patent Protection and Bypass Continuation Applications: Evaluating Benefits and Risks, Navigating Priority
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE webinar will guide patent counsel on the use of bypass continuation applications. The panel will discuss the advantages of using the application along with the potential risks. The panel will also offer best practices for using the bypass application and navigating the process.
Outline
- Bypass application
- Advantages
- Potential risks
- Bypass traps
- Navigating the process
- Best practices for using the bypass application
Benefits
The panel will review these and other key issues:
- What are the benefits of and reasons to use the bypass continuation applications?
- What are the potential risks of filing a bypass application?
- When determining whether to use a bypass application, what factors should patent practitioners consider?
Faculty
Rebecca M. McNeill
Partner
McNeill Baur
Ms. McNeill offers intellectual property strategy and advises on new application preparation, patent prosecution (U.S.... | Read More
Ms. McNeill offers intellectual property strategy and advises on new application preparation, patent prosecution (U.S. and foreign), and preparation and negotiation of IP transactions, and provides the full scope of counseling services. She has a special interest in counseling clients on patent application filing and developing worldwide prosecution strategies in concert with clients’ business goals. She has managed and directed the U.S. and international patent portfolios for U.S. clients and has overseen the U.S. patent portfolio for international clients in Europe and Asia.
Close
Lisa L. Mueller, J.D., B.S.
Shareholder
Casimir Jones
For over 25 years, Ms. Mueller has provided strategic counsel on complex patent issues to clients in the... | Read More
For over 25 years, Ms. Mueller has provided strategic counsel on complex patent issues to clients in the pharmaceutical, biopharmaceutical, biotechnology, and chemistry sectors. She brings in-depth knowledge and extensive experience to her work, advising clients on the global patent protection, freedom to operate, and validity of blockbuster drugs they aim to produce and distribute. With a background in chemistry and biology, she provides advice on the full spectrum of global intellectual property portfolio management, including patent prosecution, opposition, and other post-grant proceedings, and diverse regulatory matters. Since 2001, she has worked closely with in-house legal departments of global pharmaceutical firms regarding their patent development and enforcement strategies. In this partnership, Ms. Mueller provides training to new in-house counsel. She meets with scientists and other business development to anticipate and resolve a wide array of problems, including navigation of FDA approval. A thought leader on pharmaceutical and biopharmaceutical patent law, Ms. Mueller frequently speaks to legal and industry groups and publishes widely.
Close
Nicholas J. Landau, Ph.D.
Shareholder
Maynard Cooper Gale
Dr. Landau is a seasoned Patent attorney with 18+ years of legal experience and doctoral level training in... | Read More
Dr. Landau is a seasoned Patent attorney with 18+ years of legal experience and doctoral level training in environmental/industrial microbiology. As a Shareholder in the Firm’s Intellectual Property Group, he focuses his practice on patent drafting, patent prosecution, managing international patent portfolios, providing legal analysis and opinions, and brand protection and enforcement. Dedicated to intellectual property law and the advancement of biological science, he is active in the biotechnology industry, serving as a board member of BIO Alabama, former Chair of the AIPLA Biotechnology Committee, and an Adjunct Professor of Law at Cumberland School of Law.
Close